Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 6UNKNOWN 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Cisplatin 15Paclitaxel 14Taxes 10Cyclophosphamide 9Carboplatin 9Gemcitabine 7Platinum 61,2-diaminocyclohexaneplatinum II citrate 6Trastuzumab 5Radiotherapy 5Oxaliplatin 5Doxorubicin 5Docetaxel 5Cytarabine 5Capecitabine 5Brachytherapy 5fludarabine 4Rituximab 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Fluorouracil 4Dexamethasone 4Watchful Waiting 3Radiotherapy, Conformal 3Pemetrexed 3Nimorazole 3Lenalidomide 3Imatinib Mesylate 3Idarubicin 3Gene Expression Profiling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × NETWORK × Olanzapine × Clear all
NCT02400866 2015-03-27

A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy

Korean South West Oncology Group

Phase 2 Unknown
58 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡